BioCryst receives additional NIAID funding of $2.5M for BCX4430 development BioCryst announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND. This option represents an additional $2.5M to BioCryst in order to advance the development of BCX4430 as a treatment for Marburg virus disease. The total funding could be up to $22M over five years and advance the program through Phase 1 trials, if all contract options are exercised. The goals of this contract are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.